Currently, molecular markers for adult glioma classification and prognosis include IDH1/2 mutations, homozygous deletion of CDKN2A and/or CDKN2B, EGFR amplification, and TERT promoter mutation. This evidence concerns the gene IDH1 and central nervous system cancer.